实用临床医药杂志2025，Vol.29Issue(3)：17-21,29,6.DOI:10.7619/jcmp.20242691
肺免疫预后指数与信迪利单抗治疗晚期非小细胞肺癌患者预后的相关性
Correlation between the pulmonary immune prognostic index and prognosis of advanced non-small cell lung cancer patients treated with sintilimab
摘要
Abstract
Objective To analyze the correlation between the pulmonary immune prognostic index(LIPI)and the prognosis of patients with advanced non-small cell lung cancer(NSCLC)treated with sintilimab.Methods A total of 145 patients with advanced NSCLC were selected as study subjects.All patients received treatment with sintilimab,and their clinical baseline data were recorded.Accord-ing to the LIPI score,patients were divided into low-risk,intermediate-risk,and high-risk groups.The correlation between LIPI and the prognosis of advanced NSCLC patients was analyzed.Factors in-fluencing progression-free survival(PFS)and overall survival(OS)were identified.Results Univa-riate analysis showed that patient age,smoking status,pathological type,clinical stage and LIPI were factors affecting PFS(P＜0.05);age,pathological type,clinical stage and LIPI were factors affecting OS(P＜0.05).Multivariate Logistic regression analysis revealed that age of 60 to 70 years,age＞70 years,adenocarcinoma,stage Ⅳ and high-risk LIPI were independent prognostic factors of PFS(P＜0.05);age＞70 years,poor stage Ⅳ,adenocarcinoma and high-risk LIPI were independent prognos-tic factors of OS(P＜0.05).LIPI influenced patient's prognosis,with low-risk patients showing better outcomes and longer median PFS and OS.Conclusion LIPI is correlated with the prognosis of advanced NSCLC patients treated with sintilimab.Patients with a low-risk LIPI assessment benefit more from sintilimab treatment.关键词
非小细胞肺癌/信迪利单抗/肺免疫预后指数/总生存期/无进展生存期Key words
non-small cell lung cancer/sintilimab/pulmonary immune prognostic index/overall survival/progression-free survival分类
医药卫生引用本文复制引用
温旭智,许春妮,洪国标,骆学新,陈雯微..肺免疫预后指数与信迪利单抗治疗晚期非小细胞肺癌患者预后的相关性[J].实用临床医药杂志,2025,29(3):17-21,29,6.基金项目
浙江省中医药科技计划项目(2023ZL185) （2023ZL185）
